US Tariffs Face Scrutiny After Supreme Court Ruling, EU Monitors Response

Washington D.C. – The US trade landscape is in flux following a Supreme Court ruling on Friday, February 20, 2026, that deemed former President Donald Trump’s sweeping “reciprocal” global tariffs unconstitutional. The decision has prompted immediate responses from the Trump administration and raised concerns among European officials regarding potential alternative tariff measures.

Supreme Court Ruling and Trump’s Response

The Supreme Court’s decision centers on tariffs implemented during Trump’s second term. In response, President Trump announced an executive order imposing a 10% global tariff, leveraging Section 122 of the 1974 Trade Act. The Journal reports this move as a direct reaction to the court’s rebuke.

EU Concerns and Monitoring

European officials are closely monitoring the situation, with Tánaiste and Minister for Finance Simon Harris stating the Irish government is “closely monitoring the situation.” The Irish Times highlights the EU’s concern that the Trump administration may seek alternative legal justifications for imposing tariffs.

The European Commission is seeking clarity on the ruling, potentially opening the door for businesses to reclaim tariffs already paid and re-evaluate investments made based on the previous tariff policy. The Irish Mirror notes that the US Treasury had collected over $133 billion from the tariffs as of December 2025.

Sector-Specific Impacts and Potential Risks

While the Supreme Court ruling impacts the “reciprocal” tariffs, it does not affect tariffs imposed under Section 232 investigations, which focus on national security concerns. These investigations cover sectors crucial to Ireland, including pharmaceuticals, semiconductors, commercial aircraft, medical devices and more. BreakingNews.ie emphasizes that the pharmaceutical industry in Ireland is particularly vulnerable, as Trump could potentially introduce tariffs on pharmaceutical imports under the guise of national security.

Despite previous threats, Trump has not yet levied tariffs on pharmaceutical products. However, a previous EU-US deal capped any future tariffs on such imports at 15%.

EU-US Trade Deal and Future Outlook

The implications of the court ruling on the EU-US trade deal agreed upon in July 2025 remain unclear. The deal aimed to avert a trade war by establishing a 15% tariff cap, but senior EU officials anticipate Trump may pursue alternative means to reimpose tariffs. The Irish Times reports that the EU is analyzing the ruling and will engage with the US administration to understand their next steps.

Simon McKeever, CEO of the Irish Exporters Association, cautioned that while the ruling initially appears positive for many sectors, it does not extend to pharmaceuticals, steel, aluminum, or their derivatives. Fergal O’Brien, executive director with Ibec, noted the ruling weakens the US government’s position on broad tariffs but acknowledged the potential for the Trump administration to utilize other trade instruments.

Key Takeaways

• The US Supreme Court ruled Trump’s “reciprocal” global tariffs unconstitutional.
• President Trump responded by announcing a 10% global tariff using Section 122 of the 1974 Trade Act.
• The EU is closely monitoring the situation and seeking clarity from the US administration.
• Tariffs imposed under Section 232 investigations, related to national security, remain in effect.
• The pharmaceutical sector is identified as particularly vulnerable to potential future tariffs.